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Edited by Takashi GojoboriAbstract Previous studies showed that progesterone receptor
(PR), one of the hormone receptor superfamily, was only
connected with the sex-correlated cancers such as breast cancer,
endometrial cancer, prostate cancer, etc. This article deals with
the PR gene in leukemia. We investigated the methylation status
and the expression of the two diﬀerent PR isoforms, PRA and
PRB, in three leukemia cancer cell lines using methylation-
speciﬁc polymerase chain reaction (MSP-PCR) and reverse
transcription-PCR. The correlation of PR methylation and
expression together with DNA methyltransferase (DNMT1) was
further studied. We found that DNMT1 is required to maintain
CpG methylation and aberrant gene silencing of PR gene in
human leukemia cancer cells. The activity of 5-aza-20-deoxycyt-
idine in demethylation and gene reactivation may be through
depleting cellular DNMT1 levels. In addition, extensive meth-
ylation of PRA and PRB was also observed in leukemia samples.
Our results suggest that PR CpG island aberrant hypermethy-
lation could be one molecular and genetic alteration in leukemia.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Progesterone receptor; Promoter methylation;
Leukemia; DNA methyltransferase; Methylation-speciﬁc PCR1. Introduction
Progesterone receptor (PR) is a transcription factor of the
steroid hormone receptor superfamily. The human PR gene
encodes two isoforms, hPRA (79 kDa) and hPRB (109 kDa),
which diﬀer in both their N-terminal sequences and biological
activities. The hPRB transcript is preferentially induced by
estrogen receptor (ER). Since ligand-bound ER is a major
transcriptional activator of hPRB gene expression, the presence
of PR is indicative of functional ER [1]. The physiological ac-
tion of PRA and PRB and their regulation of gene expression in
target tissues are summarized in [2,3]. PR has been described in
many normal and neoplastic tissues [4–7]. It correlates with
cellular proliferation and endocrine treatment [2,8].
Tumors with inactivated PR gene lack PR transcription, but
no mutations within the DNA-binding domain of the ER gene
or major polymorphisms or deletions within the PR gene have* Corresponding author. Fax: +86-23-65424208.
E-mail address: a65424208@online.cq.cn (Z.-J. Liu).
Abbreviations: 5-Aza-CdR, 5-Aza-20-deoxycytidine; PCR, polymerase
chain reaction; DNMT, DNA methyltransferase; MSP, methylation-
speciﬁc PCR; RT-PCR, reverse transcription PCR
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doi:10.1016/j.febslet.2004.04.044been identiﬁed [9,10]. Acquired loss of transcription of these
hormone receptor genes is a potential mechanism of resistance
to hormonal therapies. One mechanism by which gene ex-
pression can be silenced is aberrant methylation of CpG is-
lands in the 50-regulatory region and ﬁrst exon of genes [11].
Methylation of these islands has been shown to inhibit tran-
scription directly or stabilize chromatin in a conformation that
prevents transcription [12].
Normal hematopoietic cells appear to be partly regulated by
endocrine factor ER [13]. Issa et al. investigated the methyla-
tion state of the ER gene CpG island in normal and neoplastic
bone marrow cells and observed that it is methylated in nearly
90% of human leukemias and lymphomas [13]. This molecular
alteration points to a potentially important role for loss of ER
function in the pathogenesis of human leukemias.
In this study, by using methylation-speciﬁc polymerase chain
reaction (MSP-PCR) and reverse transcription PCR (RT-PCR)
assay method, we have tested the hypothesis that the PR gene
might also be involved in leukomogenesis. We analyzed the ex-
pression and methylation status of two PR isoforms gene in
leukemia cell lines. The results indicate that the aberrant meth-
ylation could be one molecular and genetic alteration in leuke-
mia andmight provide a clinically useful, tumor-speciﬁcmarker.2. Materials and methods
2.1. Cell culture and treatment with 5-Aza-CdR
The leukemia cell lines, Jurkat, K562 and HL-60, are obtained from
the Southwest Hospital (Chongqing, PRC). All cell lines were cultured
in RPMI 1640 supplemented with 10% fetal calf serum. The cells were
treated with a freshly prepared solution of 5-aza-20-deoxycytidine (5-
Aza-CdR, Sigma). On day 1, a ﬁnal concentration of 2 lM 5-Aza-CdR
in PBS was added to the ﬂask. The next day, the medium was changed
to RPMI 1640. On days 3 and 5, the cells were treated with 4 lM 5-
Aza-CdR two times. On days 4 and 6, the medium was changed to
RPMI 1640 two times. On day 7, the cells were harvested [14].
2.2. Tissue samples
44 cases of bone marrow samples from patients with leukemia and
10 cases of bone marrow samples from normal persons were obtained
from Laboratory of Hematology, Southwest Hospital.
2.3. DNA and RNA preparation
Total DNA and RNA were extracted from various cancer cell lines
and bone marrow samples using Tirpure-Isolation-Reagent (Roche,
USA).
2.4. Sodium bisulﬁte treatment
DNA bisulﬁte treatment was carried out using the reagents provided
in the CpGenome DNA Modiﬁcation Kit (Intergen, Purchase, NY,blished by Elsevier B.V. All rights reserved.
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with sodium bisulﬁte for 18 h. Modiﬁed DNA was resuspended in 30 ll
of TE (10 mM Tris/0.1 mM EDTA, pH 7.5) and stored immediately at
)20 C [15,16].
2.5. Methylation-speciﬁc PCR analysis conditions
PCR was performed using Taq polymerase (Promega) and the hot
start procedure [17]. The PR speciﬁc primer sets are designed to locate
on the 50-upper region of each promoter for distinguishing PRA and
PRB separately [18]. Primer set U will anneal to unmethylated DNA
that has undergone a chemical modiﬁcation. Primer setMwill anneal to
methylated DNA that has undergone a chemical modiﬁcation. The
unmethylated or methylated sequence of promoter A of this gene was
detected with PRA-Uf and PRA-Ur or PRA-Mf and PRA-Mr, re-
spectively. The unmethylated or methylated sequence of promoter B of
this gene was detected with PRB-Uf and PRB-Ur or PRB-Mf and PRB-
Mr, respectively (Table 1). The PCR mixture (50 ll) contained 2.0 mM
MgCl2, 0.2 mM each of 4 dNTPs, 0.8 mM each of oligonucleotide
primers and 2.5 units of Taq DNA polymerase. PCR conditions are
listed in Table 1. After PCR, 9 ll of PCR product was mixed with 1.5 ll
of 10 loading dye and then run on 2% agarose gel. Electrophoresis
was carried out at 100 V at ambient temperature. The bands on the gels
were visualized by ethidium bromide staining. The PCR products for
PRA and PRB were 99 and 200 base pairs, respectively.
2.6. RT-PCR
RT-PCR kits (TaKaRa, Japan) were used to synthesize cDNA from
2 lg of total RNA using random hexamer primers. cDNA synthesis was
carried out as suggested by the kit protocol, using AMV reverse
transcriptase. The RT was carried out for 45 min at 45 C, after an
incubation at 99 C for 5 min to inactivate the reverse transcriptase. 5 ll
of cDNA was used to amplify regions of PR common to both isoforms
and region unique to PRB. b-Actin cDNA fragments was also ampliﬁed
as a positive control (Table 1). Primers for b-actin were chosen spe-
ciﬁcally to cross two exons in the b-actin gene. In the presence of
contaminating genomic DNA, additional larger bands would be am-
pliﬁed. The lack of ampliﬁcation of any larger bands would indicate
that there was no contamination with any genomic DNA [18]. The PCR
conditions are as follows: pre-PCR incubation at 94 C for 2 min; de-Table 1
PCR primer sequences and PCR conditions for PR and DNMT1
Primer Sequence Pre-PCR
incubation
Dena
PRA-Wf 50-ACGGGCTACTCTTCCCTCG-30 94 C, 5 min 94 C
PRA-Wr 50-TGGAATATGCGCCCTCCACG-30
PRA-Uf 50-ATGGGTTATTTTTTTTTTG-30 94 C, 5 min 94 C
PRA-Ur 50-TAAAATATACACCCTCCACA-30
PRA-Mf 50-ACGGGTTATTTTTTTTTCG-30 95 C, 5 min 94 C
PRA-Mr 50-TAAAATATACGCCCTCCACG-30
PRB-Wf 50-TGACTGTCGCCCGCAGTACG-30 95 C, 5 min 94 C
PRB-Wr 50-CGGCAATTTAGTGACACGCG-30
PRB-Uf 50-TGATTGTTGTTTGTAGTATG-30 95 C, 5 min 94 C
PRB-Ur 50-CAACAATTTAATAACACACA-30
PRB-Mf 50-TGATTGTCGTTCGTAGTACG-30 95 C, 5 min 94 C
PRB-Mr 50-CGACAATTTAATAACACGCG-30
RT-PCR AB-f 50-AGCCGGTCCGGGTGCAAG-30 94 C, 2 min 94 C
RT-PCR AB-r 50-CCACCCAGAGCCCGAGGG-30
RT-PCR B-f 50-ACTGAGCTGAAGGCAAAGGGT-30 94 C, 2 min 94 C
RT-PCR B-r 50-GTCCTGTCCCTGGCAGGGC-30
RT-PCR
DNMT1-f
50-GTGGCAGTGGACGGAGCAAG-30 94 C, 2 min 94 C
RT-PCR
DNMT1-r
50-AACCAGTGGGCGTGAAACAT-30
b-Actin-f 50-AAGGCCAACCGCGAGAAGAT-30 94 C, 2 min 94 C
b-Actin-r 50-TCGGTGAGGATCTTCATGAG-30nature at 94 C for 30 s; annealing at 62 C for 30 s; extension at 72 C
for 30 s; 35 cycles; ﬁnal extension at 72 C for 8 min. After PCR, 8 ll
product was mixed with 1 ll of 10 loading dye and then run on 2%
agarose gel. Electrophoresis was carried out at 100 V at ambient tem-
perature. The bands on the gels were visualized by ethidium bromide
staining. Electrophoresis proﬁles were analyzed by the software, Gel-
Pro3.1 (Media Cybernetics Inc., USA). The ratio of the integrated
optical density (IOD) of PR and b-actin represented the mRNA level.
PRA mRNA cannot be distinguished from PRB by conventional RT-
PCR because PRA has no speciﬁc sequence to distinguish it from PRB
mRNA. Therefore, we measured PRAB and PRB mRNA. The primes
for DNA methyltransferase (DNMT1) were also listed in Table 1. The
PCR product for DNMT1 was 361 base pairs [19].
2.7. Antisense methyltransferase oligo treatment
The antisense methyltransferase oligo was designed to hybridize to
the 50-untranslated region [19,20]. Antisense sequence MG88 (50-
AAGCATGAGCACCGTTCTCC-30); Control sequence MG208 (50-
AACGATCAGGACCCTTGTCC-30) with six mismatch bases. The
two oligos were 20-O-methyl modiﬁcation at the ﬁrst and the last four
bases. Cells were treated with these oligos at doses from 0 to 70 nM in
the presence of DOSPER Liposomal Transfection Reagent (Roche). In
the ﬁrst day, cells were cultured in RPMI 1640 supplemented with 10%
fetal calf serum (5% CO2), then transfected with antisense or control
oligo for 6 h. After that, the cells were washed with PBS twice and
changed into medium of RPMI 1640 supplemented with 10% fetal calf
serum. The cells were harvested 24 h later. For continuous transfec-
tion, cells were transfected with antisense oligo or control oligo every
day and were split every second day.3. Results
3.1. Methylation status of PRA and PRB before and after
2-Aza-CdR treatment
By MSP without 5-Aza-CdR treatment, methylation bands
were observed whereas unmethylated bands did not appear in
either one of the three cell lines used (Fig. 1A and B). After 5-ture Annealing Extension Cycle Final
incubation
, 30 s 63 C, 30 s 72 C, 30 s 40 72 C, 8 min
, 30 s 55 C, 30 s 72 C, 30 s 40 72 C, 8 min
, 30 s 55 C, 30 s 72 C, 30 s 40 72 C, 8 min
, 30 s 63 C, 30 s 72 C, 30 s 40 72 C, 8 min
, 30 s 55 C, 30 s 72 C, 30 s 40 72 C, 8 min
, 30 s 55 C, 30 s 72 C, 30 s 40 72 C, 8 min
, 30 s 62 C, 30 s 72 C, 30 s 35 72 C, 8 min
, 30 s 62 C, 30 s 72 C, 30 s 35 72 C, 8 min
, 30 s 62 C, 30 s 72 C, 30 s 35 72 C, 8 min
, 30 s 62 C, 30 s 72 C, 30 s 35 72 C, 8 min
Fig. 2. The mRNA expression of PRAB, PRB after (1–4; 9–12) and
before (5–8; 13–16) 50-Aza-CdR treatment. L – DNA marker; 1,5,9,
13– Jurkat; 2,6,10,14 – K562; 3,7,11,15 – HL-60; 4,8,12,16 – b-actin.
Table 2
Changes of DNMT1 mRNA before and after 5-Aza CdR treatment
(x S.D.)
HL-60 K562 Jurkat
Before 0.857 0.025 0.940 0.026 0.987 0.021
After 0.337 0.025 0.340 0.026 0.360 0.026
P < 0:01 P < 0:01 P < 0:01
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Fig. 3. The changes of mRNA expression of DNMT1 after antisense
DNMT1 oligo treatment. MG88, antisense DNMT1 oligo; MG208,
control oligo.
Fig. 1. (A) Methylation status of PRA before and after treatment with
demethylating reagent 50-Aza-CdR. U, unmethylated bands; M,
methylated bands; L, marker. (B) Methylation status of PRB before
and after treatment with demethylating reagent 50-Aza-CdR. U, un-
methylated bands; M, methylated bands; L, DNA marker. (C)
Changes of DNMT1 mRNA before and after 5-Aza CdR treatment.
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of PRA and PRB by MSP (Fig. 1A and B).
3.2. The mRNA expression of PRAB and PRB before and after
2-Aza-CdR treatment
Before 2-Aza-CdR treatment, no PRAB or PRB expression
was found by RT-PCR (Fig. 2). Treatment of cell lines with 2-
Aza-CdR restored PRAB and PRB expression in all cancer cell
lines (Fig. 2).
3.3. The mRNA expression of DNMT1 before and after
2-Aza-CdR treatment
Treatment of cell lines with 2-Aza-CdR lowered the mRNA
expression of DNMT1 about two times compared with mRNAexpression of DNMT1 before 2-Aza-CdR treatment (Fig. 1C,
Table 2).
3.4. The changes of mRNA expression of DNMT1 after
antisense DNMT1 oligo treatment
We used an antisense DNMT1 oligo (MG88) and a control
oligo (MG208) to abrogate DNMT1. The results showed that
DNMT1 was signiﬁcantly downregulated in the three cell lines
after transfection. Fig. 3 shows the DNMT1 mRNA expres-
sion in HL-60. The similar result is obtained in K562 and
Jurkat.
3.5. The changes of methylation status of PRA and PRB after
antisense DNMT1 oligo treatment
By MSP after antisense DNMT1 oligo MG88 treatment,
both methylation bands and unmethylated bands were
observed in all three cell lines, whereas in the control
(MG208 treatment) only methylated bands appeared
(Fig. 4).
Fig. 4. Methylation status of PRA and PRB after 4 days DNMT1
oligo treatment. MG88 – DNMT1 antisense oligo; MG208 – control
oligo; U – unmethylated bands; M – methylated bands; L – DNA
marker; 2,5,9,12 – Jurkat; 3,6,10,13 – K562; 4,7,11,14 – HL-60.
330 Z.-J. Liu et al. / FEBS Letters 567 (2004) 327–3323.6. The relationship of PRB mRNA expressions and the MG88
treatment
The PRB mRNA was increased in a time-dependent manner
in the antisense oligo MG88 treatment group within 8 days in
three cancer cell lines (Fig. 5).Table 3
Summary of PR methylation in leukemia
Methylated
PRA PRB
ALL 63.6% (7/11) 54.5% (6/11)
CLL 62.5% (5/8) 75.0% (6/8)
AML 66.7% (10/15) 60.0% (9/15)
CML 70.0% (7/10) 60.0% (6/10)
Normal 0% (0/10) 0% (0/10)
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Fig. 5. Relation between PRB mRNA expressions and the time of
MG88 treatment.3.7. Methylation frequencies of the PRA and PRA genes in
primary leukemia samples
To determine normal patterns of PR methylation in hema-
topoietic cells, we studied bone marrow DNA from 10 healthy
individuals. MSP results showed that normal bone marrow
cells are unmethylated in the PR double promoters CpG is-
lands. Having established that normal hematopoietic cells are
unmethylated at the PR CpG island, we next determined the
methylation state of this gene in 44 human leukemia samples.
Table 3 is the summary of PR methylation in leukemia samples
and normal controls.4. Discussion
The research of promoter methylation was mainly focused
on mono-promoter gene before. But the gene regulation of
multiple promoters is more complex than that of mono-pro-
moter. Research of methylation of PR with two promoters was
mainly focused on steroid-related neoplasms [1,18,21] before.
This experiment was designed to disclose the methylation
status of PR double promoters in leukemia and clarify the
signiﬁcance of PR promoter methylation in silencing PR ex-
pression in leukemia. The correlations of PR methylation and
PR expression together with the DNMT1 was further studied,
which provided theory basis for the relation between the epi-
genetic and the formation of neoplasm and new direction for
the therapy of neoplasm.
Sasaki et al. [18] investigated the methylation status of PRA
and PRB in UEC cell lines using MSP. They discovered that
PRB is methylated in all human UEC cells, whereas PRA is
unmethylated. We investigated the methylation status of PRA
and PRB in the gastric cancer cell line, colorectal cancer cell
line, lung cancer cell line, pancreas cancer cell line and epi-
dermoid cancer cell line [22]. We discovered that PRA
and PRB are both methylated in all the cancer cell lines
investigated.
In this study, we studied the methylation status of PRA and
PRB in leukemia cell lines using MSP. The results showed that
CpG islands of PRA and PRB promoters were hypermethy-
lated without unmethylation bands in three leukemia cell lines
Jurkat, K562 and HL-60. In addition, the mRNA expression
of PRAB and PRB was inactivated in the three leukemia cell
lines researched.
To understand whether PR mRNA expression is inactivated
by methylation, we treated cells with 5-Aza-CdR. The treat-
ment of 5-Aza-CdR restored PRB and PRAB expression in all
cell lines researched. The results showed clearly that there is a
close relationship between the inactivation of PR gene and
abnormal methylation of PR in leukemia cells.Unmethylated
PRA PRB
45.5% (5/11) 45.5% (5/11)
37.5% (3/8) 25.0% (2/8)
40.0% (6/15) 53.3% (8/15)
30.0% (3/10) 50.0% (5/10)
100% (10/10) 100% (10/10)
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methylation of PR gene in leukemia cell, we used antisense
methyltransferase oligo (MG88) to study the inﬂuence of
DNMT1 mRNA expression to PR methylation. PR methyla-
tion is in accordance with an increase of DNMT1 mRNA in
this study. After the MSP analysis, we demonstrated the evi-
dence of DNA methylation in leukemia cell lines. We also
found that a high level of DNMT was related to low PR
mRNA expression and methylation of the promoter site. The
antisense methyltransferase oligo in reactivating this gene
further identiﬁed the role of DNMT1 in PR gene silencing.
Kanai et al. [23] reported that overexpression of DNMT1
mRNA was signiﬁcantly associated with CpG island methyl-
ator phenotype in 23% of colorectal cancers and 31% of
stomach cancers. However, some other studies have failed to
demonstrate a correlation between the level of DNMT1 ex-
pression in cancer cells and the state of methylation of the
tumor suppressors [24,25]. Our study supports the hypothesis
that PR gene silencing through DNA methylation may be
mediated by an increase of DNMT in leukemia cancer cell
lines.
Melki et al. [26] developed a standardized competitive RT-
PCR assay to measure the level of DNMT transcripts in pa-
tients with acute leukemia. They observed a 4.4-fold mean
increase in the level of DNMT mRNA compared with normal
bone marrow. Their results support the hypothesis that
an increase in DNMT activity is associated with malig-
nant hematological diseases and may constitute a key step in
carcinogenesis.
To further understand the role of DNMT1 in PR gene si-
lencing in leukemia, we used an antisense methyltransferase
oligo to test the hypothesis that a high level of DNMT is the
main cause of the hypermethylation in the CpG island and
contributes to the loss of PR gene mRNA expression. Al-
though DNMT inhibitor 5-Aza-CdR can produce similar
results and is widely used to study the reexpression of genes
silenced by promoter methylation [27], this inhibitor is mu-
tagenic and may cause DNA damage. To exert their biolog-
ical eﬀect, 5-Aza-CdR must be incorporated into the DNA
where they covalently trap the bulky 190 kDa DNMT onto
the DNA [28], so that they may alter gene expression by
mechanisms unrelated to the inhibition of DNMT [29]. An-
tisense oligos have been proven to be an eﬀective approach in
many areas of cancer research and have been shown to act
through an Rnase H-dependent cleavage of the target mRNA
and then turnover of previously synthesized protein, and lead
to a reduction in target protein [27]. MG88 is termed as
second-generation antisense molecules because it contains
both phosphorothioate backbone modiﬁcations as well as a
20-O-methyl modiﬁcation to the ribose on the four 30 and 50
terminal nucleotides. The combination of these chemistries
increases stability and potency of the inhibitors, thus allowing
very low concentrations to be used experimentally, thus
minimizing non-speciﬁc eﬀects [27]. In our study, we com-
pared the eﬀect of antisense DNA DNMT1 oligo MG88 and
a control oligo with six mismatch bases. We found that
DNMT mRNA can be reduced to a very low level on the
second day after antisense oligo transfection. PR mRNA level
was upregulated in all three cell lines. This suggested that
DNMT plays an important role in PR gene silencing and
promoter CpG methylation. A previous study also demon-
strated that blocking DNMT1 by antisense oligo could acti-vate the p16 gene through demethylation [30]. This study
suggests that antisense DNMT1 can reactivate the PR gene in
human cancer cell lines.
Cancer cell lines exhibit a higher degree of methylation
than normal tissues [31]. Because cell lines are at the end
stage of carcinogenesis and they may not truly represent
each cancer in tissue. Therefore, we also performed methyl-
ation analysis using primary leukemia samples. The results
are summarized in Table 3. The methylation frequencies of
the PRA gene are 63.6% in ALL, 62.5% in CLL, 66.7% in
AML, 70% in CML and 0% in normal control. The meth-
ylation frequencies of the PRB gene are 54.5% in ALL, 75%
in CLL, 60% in AML, 60% in CML and 0% in normal
control. These data conﬁrm extensive methylation of the
PRA and PRB CpG islands in these leukemias. This aber-
rant methylation might be an important step in the evolution
of these tumors.
CpG islands are found in other members of the hormone
receptor superfamily including androgen, progesterone, and
ER genes [32–34]. Issa et al. [13] discovered that the ER
CpG island is abnormally methylated in most hematopoi-
etic neoplasms. This study observed that PR CpG island is
also abnormally methylated in leukemia neoplasms. These
results altogether supported the hypothesis that the hor-
mone receptor superfamily might be involved in normal
hematopoiesis.
In summary, this study indicated that reduced PR mRNA
expression in leukemia cell lines was in part related to DNA
methylation and a high level of DNMT. Antisense methyl-
transferase oligo can abrogate DNMT1 and increase PR
mRNA expression. We conclude that DNA methylation plays
an important role in PR gene silencing in leukemia.References
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